[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360774-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360774-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-kidney-cancer-among-patients-with-type-2-diabetes-a-population-based-cohort-study","Sodium-glucose cotransporter 2 inhibitors and the risk of kidney cancer among patients with type 2 diabetes - a population-based cohort study","","Investigate whether sodium-glucose cotransporter 2 (SGLT2) inhibitor use is associated with a lower incidence of kidney cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitor use in adults with type 2 diabetes (T2D), particularly those often accompanied by chronic kidney disease. Use nationwide Korean claims and health examination data and 1:1 propensity score matching to compare 57,103 new users in each group. Follow 408,481 person-years to assess incident kidney cancer and supporting sensitivity analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-kidney-cancer-among-patients-with-type-2-diabetes-a-population-based-cohort-study/360774/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-kidney-cancer-among-patients-with-type-2-diabetes-a-population-based-cohort-study/360774.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study question about SGLT2 inhibitors and kidney cancer?","Question",{"text":63,"@type":64},"The study evaluates whether SGLT2 inhibitor use is associated with a reduced risk of incident kidney cancer compared with DPP-4 inhibitor use in patients with type 2 diabetes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the study groups formed?",{"text":68,"@type":64},"After 1:1 propensity score matching, 57,103 new users of SGLT2 inhibitors were matched with 57,103 new users of DPP-4 inhibitors selected from 581,702 kidney-cancer-free participants.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main results regarding kidney cancer risk?",{"text":72,"@type":64},"Over 408,481 person-years, SGLT2 inhibitor use showed a 40% reduced risk of kidney cancer versus DPP-4 inhibitors (HR 0.60, 95% CI 0.40 to 0.89) and remained consistent across additional adjustments and subgroup interaction tests.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360774,1791028493,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Lee et al. BMC Medicine (2026) 24:382 [https://doi.org/10.1186/s12916-026-04864-2](https://doi.org/10.1186/s12916-026-04864-2)  \nBMC Medicine  \n RESEARCH Open Access  \nSodium-glucose cotransporter 2 inhibitors   and the risk of kidney cancer among patients with type 2 diabetes: a population-based cohort study  \nMinyoung Lee1,2†, Hokyou Lee3,4†, Eun-Jin Kim3, Dasom Son3, Hyeok-Hee Lee3,5, Hyeon Chang Kim3,4*† and Eun Seok Kang1,2*†  \nAbstract  \nBackground There is an important need to develop clinical strategies to reduce the risk of incident kidney cancer, especially in patients with type 2 diabetes (T2D) often accompanied by chronic kidney disease. Here, we investigated whether sodium-glucose cotransporter 2 (SGLT2) inhibitor use is associated with reduced kidney cancer risk compared to dipeptidyl peptidase-4 (DPP-4) inhibitor use in patients with T2D, using a nationwide cohort of the Korean national health insurance claims and health examination database.  \nMethods After 1:1 propensity score matching, 57,103 SGLT2 inhibitor new users and 57,103 DPP-4 inhibitor new users were selected from 581,702 kidney cancer-free participants, aged 20 to 79 years, who started oral glucose-lowering drugs forT2D from 2014 to 2018.  \nResults During 408,481 person-years of follow-up, 102 (25 . 0 per 100,000 person-years) new kidney cancer events occurred. SGLT2 inhibitor use was associated with a 40% reduced risk of kidney cancer compared with DPP-4 inhibitor use (18 .9 vs. 30.8 per 100,000 person-years; hazard ratio [HR] 0. 60, 95% CI 0.40 to 0 . 89) . The reduced kidney cancer risk associated with SGLT2 inhibitor use versus DPP-4 inhibitor use was consistent even after additional adjustment for all variables composing the propensity scores (HR 0 . 60, 95% CI 0.40 to 0 . 90) and regardless of age, sex, body mass index, current smoking, hypertension, medication use, or diabetic complications including nephropathy (all p>0.05 for interaction) . When comparing SGLT2 inhibitor users with 1:1 propensity score-matched non-users, SGLT2 inhibitor use was associated with a 34% reduced risk of kidney cancer compared to non-use (HR 0 . 66, 95% CI 0.49 to 0 . 89) . Conclusions Our findings suggest a potential association between SGLT2 inhibitor use and a lower risk of kidney cancer, which needs to be further validated.  \nKeywords Diabetes Mellitus, Kidney Neoplasms, Sodium-Glucose Transporter 2 Inhibitors  \n\n| †Minyoung Lee and Hokyou Lee are co-first authors. |\n| --- |\n| †Hyeon Chang Kim and Eun Seok Kang are co-corresponding authors. |\n\n*Correspondence: Hyeon Chang Kim [HCKIM@yuhs.ac](HCKIM@yuhs.ac)[ ](HCKIM@yuhs.ac)Eun Seok Kang [EDGO@yuhs.ac](EDGO@yuhs.ac)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nLee et al. BMC Medicine (2026) 24:382 Page 2 of 13  \nGraphical Abstract  \nBackground  \nSo","cbCaisHdITAQbT4D","https://ap.wps.com/l/cbCaisHdITAQbT4D","pdf",1819657,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Graphical Abstract\n## Background","[{\"question\":\"What is the study question about SGLT2 inhibitors and kidney cancer?\",\"answer\":\"The study evaluates whether SGLT2 inhibitor use is associated with a reduced risk of incident kidney cancer compared with DPP-4 inhibitor use in patients with type 2 diabetes.\"},{\"question\":\"How were the study groups formed?\",\"answer\":\"After 1:1 propensity score matching, 57,103 new users of SGLT2 inhibitors were matched with 57,103 new users of DPP-4 inhibitors selected from 581,702 kidney-cancer-free participants.\"},{\"question\":\"What were the main results regarding kidney cancer risk?\",\"answer\":\"Over 408,481 person-years, SGLT2 inhibitor use showed a 40% reduced risk of kidney cancer versus DPP-4 inhibitors (HR 0.60, 95% CI 0.40 to 0.89) and remained consistent across additional adjustments and subgroup interaction tests.\"}]","Sodium-glucose cotransporter 2 inhibitors and the risk of kidney cancer among patients with type 2 diabetes - a population-based cohort study | PDF",1790141513,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc2b108cf34fbab761510ed787c7d759.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d56743727046f7f7b6b0b082a009ae9.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8176d5d423c8c46ebeca4d34a6b74b3.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb5ed7cb37611ab899bf5542226873b1.webp",980,1301]